ZLDPF Zealand Pharma A/S

Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results

Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results

Press Release – No. 3 / 2025

Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results

Copenhagen, Denmark, February 13, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it will host a conference call on February 20, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the full year of 2024.

Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall; and Chief Commercial Officer, Eric Cox. There will be a presentation followed by a Q&A session.

The live listen-only audio webcast of the call and accompanying slide presentation will be accessible at . To receive telephone dial-in information and a unique personal access PIN, please register at . Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on the Investors section of Zealand Pharma’s website at .

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit .

Contacts:

Adam Lange (Investors)

Investor Relations Officer

Email:

Neshat Ahmadi (Investors)

Investor Relations Manager

Email:

Anna Krassowska, PhD (Media and Investors)

Vice President, Investor Relations & Corporate Communications

Email:



EN
13/02/2025

Underlying

ZLDPFZealand Pharma A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

BC-bc user ... (+8)
  • BC-bc user
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Wim Lewi
COMB Compagnie du Bo...
JEN JENSEN-GROUP ... (+9)

Morning Notes : ATEB BB, COMB BB, BPOST BB, ELI BB, GLPG NA, JEN BB, H...

: ATEB BB, COMB BB, BPOST BB, ELI BB, GLPG NA, JEN BB, HYSG BB, ZEAL DC, ECMPA NA

COMB COMPAGNIE DU BOIS SAUVAGE SA
JEN JENSEN-GROUP
ELI ELIA GROUP SA/NV
ZLDPF ZEALAND PHARMA A/S
BPOST BPOST SA
ATEB ATENOR S.A.
GLOG GLOBAL GRAPHICS S.A.
GLPG GALAPAGOS NV
ECMPA EUROCOMMERCIAL PROPERTIES NV
5h / 42m 5h / 42m 1 EN
Jacob Mekhael
  • Jacob Mekhael
ZLDPF Zealand Pharma ...

Zealand Pharma Petrelintide shows modest weight loss but excellent tol...

Zealand reported mixed results from the phase 2 (ZUPREME-1) trial of petrelintide in overweight/obesity, showing a modest 10.7% weight loss at 42 weeks, while demonstrating excellent tolerability. We think this outcome makes first line positioning difficult, and view petrelintide as better suited for weight loss maintenance (subject to positive data in that setting). We adjust our peak sales estimate to $ 7b (from $ 22b), which brings down our TP to DKK 500 (from DKK 960). Given the lower upside...

ZLDPF ZEALAND PHARMA A/S
6h / 16m 6h / 16m 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma announces positive Phase 2 results for petrelintide, an...

Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity Company announcement – No. 3 / 2026 Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity Petrelintide achieved up to 10.7% mean body weight reduction at week 42 (versus 1.7% with placebo) and demonstrated placebo-like tolerabilityAt the maximally effective dose, the...

19h 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma convenes its Annual General Meeting 2026

Zealand Pharma convenes its Annual General Meeting 2026 Company announcement – No. 2 / 2026 Zealand Pharma convenes its Annual General Meeting 2026 Copenhagen, Denmark, February 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby convenes its Annual General Meeting 2026. The Board of Directors of Zealand Pharma A/S hereby convenes the Annual General Meeting of the Company to be held on: Thursday, 26 March 2026 at 03:00 PM (CET) / 9:00 (ET) The Annual General Meet...

February 19, 2026 1 EN
Mathijs Geerts Danau
  • Mathijs Geerts Danau
ZLDPF Zealand Pharma ...

Zealand Pharma FY25 results: Looking forward to petrelintide phase 2 d...

Zealand reported FY25 results, ending the year with cash of DKK 15,109m (YE24: DKK 9,022m), reinforcing the strong balance sheet. OPEX increased to DKK 2,101m (FY24: 1,324m) driven by increased R&D spending related to the ongoing petrelintide phase 2 trials. For FY26, Zealand guides OPEX of DKK 2,700-3,300m, due to continued investment in the petrelintide franchise. We look forward to the read-out of the petrelintide phase 2 trial in obesity expected in 1Q26, which could confirm petrelintide's p...

ZLDPF ZEALAND PHARMA A/S
02/19/26 February 19, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch